Definiens
Provider of image analysis technology for digital pathology.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
$150m Valuation: $150m 31.7x EV/Revenue | Acquisition | ||
| Total Funding | 000k | ||
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 41 % | 15 % | 17 % | (2 %) | (5 %) | 21 % | 17 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (16 %) | (19 %) | (28 %) | (70 %) | (14 %) | 19 % | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (21 %) | (29 %) | (40 %) | (111 %) | (22 %) | 12 % | 13 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 40 % | 36 % | 49 % | 43 % | - | - | - |
Source: Company filings or news article
Related Content
Definiens AG, established in 1996 by the Nobel laureate Dr. Gerd Binnig, emerged from his research in cognitive science and pattern recognition. Dr. Binnig, a physicist who received the Nobel Prize in 1986 for co-inventing the scanning tunneling microscope, sought to apply principles of human cognition to data analysis, leading to the creation of the Definiens Cognition Network Technology®. This foundational technology mimics human cognitive processes to analyze and interpret images, a capability that positioned the company in the field of quantitative digital pathology. The firm is headquartered in Munich, Germany, and has a United States base in Parsippany, New Jersey.
The company's core business revolves around its Tissue Phenomics® approach, which provides detailed spatial and morphological readouts from tumor tissue biopsies. This service is primarily aimed at biotechnology and pharmaceutical companies, supporting the discovery and development of companion diagnostics and immuno-oncology biomarkers. By quantifying the expression and spatial organization of biomarkers within the tumor microenvironment, Definiens helps its clients understand drug mechanisms and patient responses, thereby accelerating clinical trials and research. Its technology can extract extensive data from a single tissue slide, offering deeper biological insights compared to traditional pathology methods. The business model is service-oriented, providing project-based support for biomarker and companion diagnostic strategies.
A significant milestone in the company's history was its acquisition by AstraZeneca in 2014 for an initial amount of $150 million, with the potential for additional predetermined milestone payments. This acquisition integrated Definiens' image analysis and data mining capabilities into AstraZeneca's drug development pipeline, particularly within its global Medicines Discovery & Development division, MedImmune. The acquisition underscored the value of Definiens' technology in advancing personalized medicine by helping to identify patients who would most benefit from specific treatments. Following the acquisition, Definiens continued to operate its services for a broad range of clients across the pharmaceutical industry.
Keywords: tissue phenomics, image analysis, digital pathology, companion diagnostics, immuno-oncology, biomarker discovery, Gerd Binnig, AstraZeneca, tumor microenvironment, personalized medicine